The Lancet Neurology reports impact of daridorexant on both

/PRNewswire/ -- As reported in the Lancet Neurology, daridorexant is the first insomnia medication to demonstrate an effect of a drug therapy to improve both...

Related Keywords

Canada , Radnor , Powys , United Kingdom , United States , Paris , France General , France , Allschwil , Switzerland General , Switzerland , Stanford , Leicestershire , American , Swiss , Andrewc Weiss , Ecole Normale Superieure Ulm , J Clin Pharmacol , Martine Clozel , Thomase Scammell , Cliffordb Saper , Thomasc Chou , Emmanuel Mignot , Christopher Clark , American Psychiatric Association , Head Of Investor Relations Corporate Communications , Stanford Center , Xxvi University , Idorsia Pharmaceuticals , Us Head Of Communications , Idorsia Ltd , National Institute Of Health Research , Us Inc , Research Society , Howard Hughes Medical Institute Investigator , National Academy Of Sciences United States , Swiss Exchange , National Center On Sleep Disorders Research Advisory , Institute Of Medicine , Idorsia Pharmaceuticals Ltd , Behavioral Sciences , National Sleep Foundation , Behavioral Sciences At Stanford University , Association Of American Physicians , Narcolepsy Network , Lancet Neurology , Stanford University , Insomnia Daytime Symptoms , Impacts Questionnaire , Chief Scientific Officer , Enforcement Administration , Full Prescribing Information , Medication Guide , Ecole Normale Superieure , Craig Reynolds Professor , Sleep Sciences , National Institute , Health Research Awards , Mcknight Neuroscience , Young Investigators , Academic Achievement Award , American Physicians , National Academy , Sleep Research Society , National Center , Sleep Disorders Research Advisory , Scientific Counselors , Thursday January , Statistical Manual , Mental Disorders , Discov Today Dis , Statistics Canada , Drug Metabolism , Neurosciences Vol , Vice President , Investor Relations , Pharmaceuticals Ltd , Idorsia Pharmaceuticals Us ,